<DOC>
	<DOC>NCT00367887</DOC>
	<brief_summary>This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs. Peg-Intron plus Rebetol in Hepatitis C Virus (HCV) genotype 1-infected subjects who are either naive to treatment or who have previously failed treatment (non-responders).</brief_summary>
	<brief_title>A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Infection with HCV genotype 1. HCV infected subjects naive to treatment. HCVinfected nonresponder subjects. Women who are pregnant or breastfeeding. ALT &gt;/ or = 5X the upper limit of normal. AST &gt;/ or = 5X the upper limit of normal.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Hepatitis C</keyword>
</DOC>